Author of

• 17556

  +

  P2.03a - Poster Session with Presenters Present (ID 464)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17576

    +

    P2.03a-020 - Metronomic Oral Vinorelbine Monotherapy in Elderly Patients with Advanced NCSLC (ID 5155)

    14:30 - 14:30  |  Author(s): A.S. Rapti
    • Abstract

    Background:
    Metronomic chemotherapy involves chronic administration of low-dose chemotherapy at regular short intervals, with the aim to induce prolonged cancer control without significant side effects.Aim: was to evaluate metronomic oral vinorelbine in elderly patients with advanced NSCLC.
    
    Methods:
    Chemotherapy naïve patients with a mean age of 72.8 yrs with NSCLC stage IIIB-IV and PS 0-2 were enrolled in this trial. Vinorelbine was administered orally at a dose of 40mg three times a week, until disease progression or unacceptable toxicities occurred.
    
    Results:
    Thirty-four patients were enrolled (19 adenoca -14 squamous -1 NSCLC). Thirty were eligible for evaluation.10 pts 33.3% had PS 2 and 7 (23.3%) had comorbidities( COPD and/or Heart failure). A partial response was observed in 6 patients (20%) and 12 (40%) had stable disease. After a median follow up period of 24.2 months, the median progression-free survival period ( PFS) was 7.00 months ( 95%CI 4.9- 9.1 months). No significant difference was found in in PFS between patients with adenoca and squamous (5.00 vs 6.39 months p>0.05) Four patients(13.3%) showed a clinical improvement changing their PS from 2 to 1. Most adverse events were grade 1- 2 (peripheral neuropathy, diarrhea and nephrotoxicity) and there was no need for dose reduction or discontinuation of vinorelbine.
    
    Conclusion:
    Considering the PFS period and the negligible toxicity metronomic oral vinorelbine seems to be a useful and safe therapeutic option for elderly patients with adnanced NSCLC.